Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
05/2003
05/01/2003US20030082204 Mixture of attenuated genetic engineered virus and carrier
05/01/2003US20030082201 Genetic engineering; polymerase chain reaction
05/01/2003US20030082200 Protein binding to immobilized vitronectin
05/01/2003US20030082199 Compositions and methods for the treatment of immune related diseases
05/01/2003US20030082198 Administering complex of heat shock protein and antigen
05/01/2003US20030082197 Administering complex of heat shock protein and antigen
05/01/2003US20030082196 Anticancer agents
05/01/2003US20030082195 Method of enhancing an immune response
05/01/2003US20030082194 Inducting immunology response; anticancer agent
05/01/2003US20030082193 Immunoassay using computer; forming vaccine, immunoglobulins
05/01/2003US20030082191 Treatment for central nervous system disorders
05/01/2003US20030082188 Treatment of prostate cancer by inhibitors of NCAM2
05/01/2003US20030082184 Uses of mammalian cytokine; related reagents
05/01/2003US20030082180 Combination of compounds that inhibit the biological effects of tnf-alpha and cd95l in a medicament
05/01/2003US20030082179 Complexing antibody with poarathyroid hormone
05/01/2003US20030082175 April receptor (BCMA) and uses thereof
05/01/2003US20030082172 Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
05/01/2003US20030082171 Deafness therapy, prevention; mylein protein vaccine
05/01/2003US20030082170 Protein from brucella species
05/01/2003US20030082166 Compounds and methods for modulating nonclassical cadherin-mediated functions
05/01/2003US20030082163 Fused cells, methods of forming same, and therapies utilizing same
05/01/2003US20030082156 Detecting disease antigen; anticancer agents
05/01/2003US20030082150 Recombinant adenoviral vectors for human tumour gene therapy
05/01/2003US20030082145 Adeno-associated virus materials and methods
05/01/2003US20030082136 Comprising allogenic line of cancer cells providing tumor-associated ganglioside, cytokines and heat shock protein for treating cancer in mammals; veterinary medicine
05/01/2003US20030082107 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
05/01/2003US20030082105 Selectively targeted fluorescent, radiolabeled, or fluorescent and radiolabeled compositions
05/01/2003CA2842429A1 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
05/01/2003CA2793019A1 Humanized antibodies
05/01/2003CA2675409A1 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
05/01/2003CA2498591A1 Immunotherapy for reversing immune suppression
05/01/2003CA2471532A1 A synthetic chimeric fusion protein with immuno-therapeutic uses
05/01/2003CA2470197A1 Mycobacterial genes down-regulated during latency
05/01/2003CA2464795A1 Thymosin augmentation of genetic immunization
05/01/2003CA2464700A1 Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
05/01/2003CA2464695A1 Il-13 mutein proteins, antibodies, compositions, methods and uses
05/01/2003CA2464372A1 Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
05/01/2003CA2464344A1 Ee3-protein family and corresponding dna sequences
05/01/2003CA2464338A1 Infectious salmon anaemia virus vaccine
05/01/2003CA2464239A1 Psma antibodies and protein multimers
05/01/2003CA2461665A1 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
05/01/2003CA2454361A1 Humanized antibodies
05/01/2003CA2429505A1 Prevention of recurrent viral disease
04/2003
04/30/2003CN1415013A BASB059 polypeptides from neisseria meningitidis
04/30/2003CN1414976A Chimeric peptides used as immunogen and its antibody, and method for their use for immunization
04/30/2003CN1414972A Method for reducing immunogenicity of heterologous proteins by elimination of T-cell epitopes
04/30/2003CN1414954A Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis (2-methoxyethoxy)-4-quinazolinamine hydrochloride, method of production and pharmaceutical uses thereof
04/30/2003CN1414864A Adhesive particle DNA constructs and method of making and using the same
04/30/2003CN1414861A Induction of mucosal immunity by vaccination via skin nute
04/30/2003CN1414102A Binding region of erythrocyte binding protein of Plasmodium vivax and Plasmodium falciform
04/30/2003CN1414018A Binding region of erythrocyte binding protein of plasmodium vivax and plasmodium falciform
04/30/2003CN1413733A Foot-and-mouth disease virus antigen preservation technology
04/30/2003CN1413732A Foot-and-mouth disease virus antigen dilution technology
04/30/2003CN1413731A Macrophage tumor vaccin and its preparation method
04/30/2003CN1413724A Brain active effect matter for prevention and curing encephalopathy and developing intelligence and its preparation method
04/30/2003CN1107115C System for expression of heterologous antigens as fusion proteins
04/30/2003CN1107072C Programing cell death induced molecule II
04/30/2003CN1106858C Vaccine composition having antitumour activity and use there of in therapy of malignant diseases
04/29/2003US6555667 Hypoxia-regulated genes
04/29/2003US6555651 Ligand binding site of rage and uses thereof
04/29/2003US6555566 Methods and materials for treating and preventing inflammation of mucosal tissue
04/29/2003US6555372 Viricides and antitumor agents
04/29/2003US6555346 Selecting a recombinant baculovirus expressing the protein, growing insect cells in a culture vessel and infecting the cells with an inoculum of baculovirus at a cell density of 1 x 105-5 x 106 cells/ml
04/29/2003US6555345 Papilloma viruses, agents for detecting them and for treating diseases caused by such viruses
04/29/2003US6555338 Given nucleotide sequence; use of polynucleotides and polypeptides in diagnostic assays, and possibly functional genomics
04/29/2003US6555331 Bacteriophage assay
04/29/2003US6555319 Antibodies for inhibiting blood coagulation and methods of use thereof
04/29/2003US6555116 Hypo-allergenic pollen protein that has been treated with thioredoxin, nicotinamide adenine dinucleotide phosphate-thioredoxin reductase (NTR) and reduced nicotinamide adenine dinucleotide phosphate (NADPH).
04/29/2003US6555115 Administering a polypeptide that contains at least one antigenic portion of a Chlamydia antigen to stimulate an immune response
04/29/2003US6555114 Immunodominant human T-cell epitopes of hepatitis C virus
04/29/2003US6555113 Elevating the ratio of circulating HDL to circulating LDL by administering a peptide conjugate of a helper T cell epitope portion linked to a B cell epitope portion; decrease in development of atherosclerotic lesions
04/29/2003US6555112 Peptides derived from the lymphadenopathy-associated virus (LAV) envelope coding region
04/29/2003US6555091 Polypeptide capable of reacting with antibodies of patients suffering from multiple sclerosis and uses
04/29/2003CA2159098C Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof
04/29/2003CA2105804C Kainate-binding, human cns receptors of the eaa5 family
04/29/2003CA2098105C Oligoside derived from an antigen polyoside obtained from a pathogen
04/29/2003CA2095855C Mycobacterium as adjuvant for antigens
04/25/2003CA2409338A1 Method for protein-preserving purification of contaminated biological liquids
04/24/2003WO2003033680A2 Kinases and phosphatases
04/24/2003WO2003033674A2 Human antibodies that have mn binding and cell adhesion-neutralizing activity
04/24/2003WO2003033670A2 Method for preparation of single chain antibodies
04/24/2003WO2003033654A2 Direct targeting binding proteins
04/24/2003WO2003033653A2 Affinity enhancement agents
04/24/2003WO2003033644A2 Peptide useful in immunomodulation
04/24/2003WO2003033533A1 Microfluidized leishmania antigen and methods of making and using thereof
04/24/2003WO2003033530A2 Mycobacterial antigens expressed under high oxygen tension
04/24/2003WO2003033520A2 Anticancer vaccine and diganostic methods and reagents
04/24/2003WO2003033029A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications
04/24/2003WO2003033021A1 Use of peptide vectors to improve the immune response to antigens
04/24/2003WO2003033015A1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY
04/24/2003WO2003032958A1 Use of a copolymer to produce a galenic form containing a peptide or a protein as active agent
04/24/2003WO2003032945A1 Binary composition for 'prime-boost' release of active ingredients like vaccines
04/24/2003WO2003032917A2 Hookworm vaccine
04/24/2003WO2003032907A2 High-concentration protein formulations and method of manufacture
04/24/2003WO2003032904A2 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
04/24/2003WO2003032814A2 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
04/24/2003WO2003032813A2 Methods for the treatment of carcinoma
04/24/2003WO2003004049A3 Use of polyclonal anti-hiv goat serum as a therapeutic agent
04/24/2003WO2002097072A3 Influenza vaccine composition
04/24/2003WO2002089841A3 Method of preventing cell death using antibodies to neural thread proteins
1 ... 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 ... 1823